ArticleIslets
Clinical utility of insulin and insulin analogs.
Article in Islets. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A Human Glucoregulatory Model for the Rational Design and Evaluation of Diabetes Therapeutics.ACS pharmacology & translational science · 2026Article
- Lentiviral GLP-1 gene therapy elicits developmental stage-dependent β-cell regeneration in diabetic rats.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Assessment of insulin pen injection practices and the effectiveness of pharmacist interventions in improving injection technique among patients with diabetes mellitus.Exploratory research in clinical and social pharmacy · 2025Article
- The 'Designer' Artificial Pancreas: How Does Current Technology Mimic Pancreatic Physiology?Cureus · 2025Review
- New horizon of the combined BCG vaccine with probiotic and liraglutide in augmenting beta cell survivalHeliyon · 2024Article
- Prandial Insulins: A Person-Centered Choice.Current diabetes reports · 2024Review
- Acute nicotine intake increases feeding behavior through decreasing glucagon signaling in dependent male and female rats.Hormones and behavior · 2024Article
- Review
- Insulin-induced lipodystrophy and predisposing factors in children and adolescents with type 1 diabetes mellitus (T1DM) in a tertiary care Egyptian center.Acta bio-medica : Atenei Parmensis · 2023Article
- Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Generation of a Beta-Cell Transplant Animal Model of Diabetes Using CRISPR Technology.Advances in experimental medicine and biology · 2023Article
- CELEBRATING 100 YEARS OF INSULIN USE.Acta clinica Croatica · 2022Review
- Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons.Current issues in molecular biology · 2022Review
- Evaluation of Patient Reported Satisfaction and Clinical Efficacy of Insulin Glargine 300 U/mL Versus 100 U/mL in Patients With Type 1 Diabetes Using Flash Glucose Monitoring System.Clinical medicine insights. Endocrinology and diabetes · 2022Article
- Genome engineering and disease modelingWorld journal of stem cells · 2021Review
- Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation.Gene therapy · 2021Article
- Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Comparison of four matrixes for diluting insulin in routine clinical measurements.Journal of clinical laboratory analysis · 2020Article
- Article
- Protective Effect of Human Mesenchymal Stem Cells on the Survival of Pancreatic Islets.International journal of stem cells · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a pandemic disease characterized by autoimmune, genetic and metabolic abnormalities. While insulin deficiency manifested as hyperglycemia is a common sequel of both Type-1 and Type-2 diabetes (T1DM and T2DM), it does not result from a single genetic defect--rather insulin deficiency results from the functional loss of pancreatic β cells due to multifactorial mechanisms. Since pancreatic β cells of patients with T1DM are destroyed by autoimmune reaction, these patients require daily insulin injections. Insulin resistance followed by β cell dysfunction and β cell loss is the characteristics of T2DM. Therefore, most patients with T2DM will require insulin treatment due to eventual loss of insulin secretion. Despite the evidence of early insulin treatment lowering macrovascular (coronary artery disease, peripheral arterial disease and stroke) and microvascular (diabetic nephropathy, neuropathy and retinopathy) complications of T2DM, controversy exists among physicians on how to initiate and intensify insulin therapy. The slow acting nature of regular human insulin makes its use ineffective in counteracting postprandial hyperglycemia. Instead, recombinant insulin analogs have been generated with a variable degree of specificity and action. Due to the metabolic variability among individuals, optimum blood glucose management is a formidable task to accomplish despite the presence of novel insulin analogs. In this article, we present a recent update on insulin analog structure and function with an overview of the evidence on the various insulin regimens clinically used to treat diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.